GLIPIZIDE; METFORMIN HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for glipizide; metformin hydrochloride and what is the scope of patent protection?

Glipizide; metformin hydrochloride is the generic ingredient in two branded drugs marketed by Epic Pharma Llc, Heritage, Novitium Pharma, Sun Pharm Inds Inc, Teva Pharms, Zydus Pharms Usa Inc, and Bristol Myers Squibb, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Nine suppliers are listed for this compound.

Summary for GLIPIZIDE; METFORMIN HYDROCHLORIDE

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	9
Clinical Trials:	11
DailyMed Link:	GLIPIZIDE; METFORMIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for GLIPIZIDE; METFORMIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Catholic University of Korea	Phase 4
Merck Sharp & Dohme Corp.	Phase 4
Bristol-Myers Squibb	Phase 4

See all GLIPIZIDE; METFORMIN HYDROCHLORIDE clinical trials

Pharmacology for GLIPIZIDE; METFORMIN HYDROCHLORIDE

Drug Class

Biguanide Sulfonylurea

Anatomical Therapeutic Chemical (ATC) Classes for GLIPIZIDE; METFORMIN HYDROCHLORIDE

A10BA	Biguanides
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

A10BB	Sulfonylureas
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for GLIPIZIDE; METFORMIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novitium Pharma	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078083-001	Apr 12, 2007		DISCN	No	No
Zydus Pharms Usa Inc	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	078905-003	Jan 31, 2011	AB	RX	No	No
Teva Pharms	GLIPIZIDE AND METFORMIN HYDROCHLORIDE	glipizide; metformin hydrochloride	TABLET;ORAL	077270-003	Oct 28, 2005	AB	RX	No	Yes

GLIPIZIDE; METFORMIN HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Market Dynamics for Glipizide and Metformin Hydrochloride?

The market for glipizide and metformin hydrochloride, primarily used in type 2 diabetes management, remains robust due to increasing global diabetes prevalence and evolving treatment guidelines. Both drugs are listed on the WHO Essential Medicines List and in most national formularies for initial or adjunct therapy.

Market Size and Growth Drivers

• The global diabetes drug market was valued at approximately USD 47.3 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030.
• Metformin hydrochloride constitutes roughly 40% of the oral antidiabetic market, driven by its first-line status. Glipizide, part of the sulfonylureas class, accounts for about 15%, benefiting from its low cost and established efficacy.
• Increased adoption in emerging markets aligns with rising healthcare infrastructure and economic growth. China and India together represent over 50% of global diabetes cases and are major consumption regions.

Competitive Landscape

• The market is dominated by generic manufacturers, with brand-controlled variants limited to innovator products like Glucotrol (glipizide) and Glucophage (metformin).
• Patent expirations: Glipizide's patent expired in the early 2000s; metformin patents expired by 2002 in most jurisdictions, facilitating generic competition.
• Price erosion has increased accessibility but constrains profit margins for manufacturers.

Regulatory Environment Influences

• The U.S. FDA classifies both drugs as safe and effective, with no recent major regulatory changes.
• Concerns over lactic acidosis linked to metformin dosing adjustments and renal impairment have led to clearer guidelines, with the FDA updating recommendations in 2016.
• Rural health policies in developing countries increasingly favor generic availability due to lower costs.

Supply Chain and Manufacturing Factors

• Raw material supply mainly in India and China influences manufacturing costs.
• Quality standards compliance remains critical amid scrutiny over drug safety, especially with the rise in counterfeit medications in emerging markets.

Challenges and Opportunities

Challenges:

• Market saturation in mature regions due to widespread use.
• Regulatory scrutiny over rare side effects that could lead to label modifications.
• Competition from newer drug classes such as SGLT2 inhibitors and GLP-1 receptor agonists.

Opportunities:

• Combination formulations can improve adherence.
• Biosimilar entries and off-patent status lead to price competition.
• Population health initiatives may expand indications or integration into combination disease management.

What Is the Financial Trajectory for These Drugs?

Revenue Trends

• The combined revenue for glipizide and metformin was approximately USD 5.4 billion in 2022.
• Market growth reflects increased patient numbers and generic competition’s impact on pricing dynamics.
• Leading generic manufacturers report annual growth rates of 4-6% driven by volume increases.

Profitability

• Margins for generic formulations average 10-15%, but can decline to 5-8% in highly commoditized markets.
• Innovation in drug formulations, such as fixed-dose combinations, offers higher margin potential but remains limited due to regulatory and patent constraints.

Cost Structure and Pricing

• Production costs are influenced by raw material expenses, regulatory compliance, and scale efficiencies.
• International prices vary: USD 2-4 per 30-tablet pack in North America; USD 0.10-0.50 in India.

Investment and R&D

• R&D expenditure on these drugs is minimal given their generic status.
• Companies focus on process optimization and supply chain efficiencies.
• Slight innovation efforts include developing combination products or improving bioavailability.

Future Revenue Projections

• Stable demand expected over the next five years owing to the chronic nature of type 2 diabetes.
• Market saturation in developed countries might suppress growth but is offset by expansion in emerging markets.
• Entry of biosimilars and generics could further reduce prices and margins.

How Do These Dynamics Compare to Other Antidiabetic Agents?

• SGLT2 inhibitors and GLP-1 receptor agonists hold higher growth rates (10-12% CAGR) but still account for a smaller market share (~15% combined).
• These newer drugs secure higher margins (20-30%) but face stricter regulatory hurdles and higher R&D costs.

Key Takeaways

• The glipizide and metformin market remains sizable but increasingly mature, with growth driven by volume rather than pricing.
• The push towards generics and biosimilars diminishes profitability but improves access.
• Emerging markets provide significant growth opportunities given their diabetes burden.
• Regulatory environments remain stable, but safety concerns could influence future prescriptions and labeling.
• The innovation focus is on combination products and improving formulations rather than new chemical entities.

FAQs

1. What factors influence the pricing of generic glipizide and metformin?
Pricing is driven by manufacturing costs, raw material availability, competition among generics, and regional pricing policies.

2. How do regulatory changes impact the market?
Regulatory updates, especially safety guidelines (e.g., renal function monitoring for metformin), can affect prescribing patterns and label claims but have had limited recent impact on market size.

3. What are the main risks for investors in this market?
Market saturation, intense price competition, regulatory scrutiny over safety issues, and the slow adoption of innovative formulations pose risks.

4. Are there emerging product innovations in this space?
Most innovation involves fixed-dose combinations, extended-release formulations, or improved bioavailability, rather than new active ingredients.

5. How significant are biosimilars and generics to future revenues?
Highly significant. Biosimilars and generics are expected to continue eroding prices but will expand overall market volume.

---

Sources:

[1] MarketsandMarkets. "Diabetes Drugs Market by Drug Type." 2022.

[2] FDA. "Update on Lactic Acidosis and Metformin," 2016.

[3] IQVIA. "Global Prescription Market Data," 2023.

[4] WHO. "Essential Medicines List," 2023.

[5] Statista. "Global Diabetes Care Market," 2022.